Study of YL201 for Patients with Advanced Solid Tumors

Inclusion Criteria

• Must be informed about the trial and voluntarily agree to participate.
• Must be 18 years or older.
• Must be in good general health, able to perform daily activities with minimal restrictions.
• Must have good organ and bone marrow function.
• Women who can become pregnant must use effective birth control and not donate eggs during the study and for a specified time after the last dose. Men must use effective birth control and not donate sperm during the study and for a specified time after the last dose.
• Must have a life expectancy of at least 3 months.
• Must be willing to attend all study visits and follow procedures.
• Must have at least one tumor that can be measured by scans.
• Must have a confirmed diagnosis of an advanced solid tumor, such as small cell lung cancer, prostate cancer, esophageal cancer, or non-small cell lung cancer, that has not responded to standard treatments or for which no standard treatment is available. For certain patients, no prior cancer treatment is allowed.

Exclusion Criteria

• Cannot be enrolled in another clinical study unless it is non-interventional or during the follow-up period of an interventional study.
• Cannot have received certain cancer treatments, including chemotherapy or targeted therapy, within a specified time before starting the study drug.
• Cannot have had major surgery recently or expect to have major surgery during the study.
• Cannot have had certain types of stem cell transplants recently.
• Cannot be taking high doses of steroids or other immune-suppressing drugs recently.
• Cannot have received a live vaccine recently or plan to receive one during the study.
• Cannot have active HIV, hepatitis B, or hepatitis C infections.
• Cannot have unresolved side effects from previous cancer treatments, unless they are mild and well-managed.
• Cannot have severe allergies to the study drug or its ingredients.
• Cannot be pregnant or breastfeeding.